Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Momentum 3.4/10 is below the 5.0 floor at $491.61 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (2); Concentration risk — Product: Rezdiffra.
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on MASH, with Rezdiffra (resmetirom) as its sole approved product (FDA-approved March 2024, EC conditional approval August 2025). Rezdiffra generated $958.4 million in product revenue in 2025; a... Read more
Sell if holding. Momentum 3.4/10 is below the 5.0 floor at $491.61 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (2); Concentration risk — Product: Rezdiffra. Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 5.6/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Madrigal Pharmaceuticals, Inc.
Latest news
- NEWS Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance — Yahoo Finance positive
- NEWS Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN — MSN positive
- NEWS Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growth - Char — ChartMill positive
- NEWS Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Singapore — Yahoo Finance Singapore positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductRezdiffra10-K Item 1A: 'Our prospects are highly dependent on the success of our only approved product, Rezdiffra'
Material Events(8-K, last 90d)
- 2026-04-28Item 5.02LOWBoard reclassified Julian C. Baker (from Class III) and Daniel J. Brennan (from Class II) as Class I directors effective April 22, 2026. Directors resigned and were simultaneously reappointed; no actual departure from the board.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.4/10 is below the 5.0 floor at $491.61 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (2); Concentration risk — Product: Rezdiffra. Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $457.89. Score 5.6/10, moderate confidence.
Take-profit target: $590.48 (+19.9% upside). Prior stop was $457.89. Stop-loss: $457.89.
Concentration risk — Product: Rezdiffra; Consecutive earnings misses (2); Negative momentum.
Madrigal Pharmaceuticals, Inc. trades at a P/E of N/A (forward 38.8). TrendMatrix value score: 5.5/10. Verdict: Sell.
23 analysts cover MDGL with a consensus score of 4.1/5. Average price target: $679.
What does Madrigal Pharmaceuticals, Inc. do?Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on MASH, with Rezdiffra (resmetirom)...
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on MASH, with Rezdiffra (resmetirom) as its sole approved product (FDA-approved March 2024, EC conditional approval August 2025). Rezdiffra generated $958.4 million in product revenue in 2025; a pivotal Phase 3 OUTCOMES trial in compensated MASH cirrhosis is enrolling with data expected in 2027.